GlassScriptPhysician profile
Stacy R Moye
NPI 1780924837
$2,199.83
in general payments reported to CMS, 2019-2025
26 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $546 · 2023: $507 · 2024: $449 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $836.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.38 | 2021-2023 | Andexxa |
| Janssen Research & Development, LLC | $149.36 | 2025 | |
| Ucb, INC. | $132.03 | 2023-2025 | Briviact, Rystiggo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.87 | 2022 | |
| Biogen, INC. | $101.12 | 2022-2025 | Vumerity, Avonex, Skyclarys |
| Boston Scientific Corporation | $88.53 | 2024 | Vercise |
| Janssen Pharmaceuticals, INC | $72.44 | 2021-2022 | |
| Amgen INC. | $69.00 | 2022-2023 | Repatha |
| Genentech USA, INC. | $60.43 | 2022-2024 | Ocrevus, Activase |
| Novartis Pharmaceuticals Corporation | $51.15 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.40 | 2022 | |
| Medtronic, INC. | $31.72 | 2023 | Endurant Iis |
| Alexion Pharmaceuticals, INC. | $30.21 | 2024 | Soliris |
| Averitas Pharma INC. | $28.66 | 2023 | Qutenza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $28.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.94 | 2024 | Austedo Xr |
| Genzyme Corporation | $24.95 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $21.81 | 2022 | |
| Amneal Pharmaceuticals LLC | $20.73 | 2022 | |
| Grt US Holding, INC. | $20.16 | 2022 | |
| Biotronik Nro, INC. | $19.86 | 2025 | |
| Eisai INC. | $17.39 | 2022 | |
| Nevro Corp. | $16.77 | 2024 | Senza |
| Lilly USA, LLC | $15.94 | 2023 | Reyvow, Emgality |
| Upsher-Smith Laboratories LLC | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Moye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.